ID   PK-8
AC   CVCL_4718
SY   PK8
DR   BTO; BTO:0004855
DR   CLO; CLO_0050112
DR   EFO; EFO_0006737
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03472951
DR   cancercelllines; CVCL_4718
DR   Cosmic; 707254
DR   Cosmic; 1066177
DR   Cosmic; 1644298
DR   DepMap; ACH-002039
DR   EGA; EGAS00001000610
DR   IARC_TP53; 14302
DR   PharmacoDB; PK8_1269_2019
DR   RCB; RCB2096
DR   RCB; RCB2700
DR   TKG; TKG 0383
DR   Wikidata; Q54947454
RX   PubMed=3547771;
RX   PubMed=11115575;
RX   PubMed=16912165;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26216984;
RX   PubMed=26589293;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Characteristics: Established from a xenograft.
CC   Doubling time: 56 hours (PubMed=3547771).
CC   HLA typing: A*24:02,31:01; B*27:04,35:01; C*04:01,12:02 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Hemizygous (PubMed=11115575).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln167Ter (c.499C>T); ClinVar=VCV000528250; Zygosity=Unspecified (PubMed=11115575).
CC   Omics: Metabolome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: RCB; RCB2096; true.
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
ST   Source(s): DepMap; PubMed=25877200; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11
ST   D16S539: 9,10
ST   D18S51: 13
ST   D21S11: 31
ST   D3S1358: 16
ST   D5S818: 13
ST   D7S820: 9,12
ST   D8S1179: 13,15
ST   FGA: 23 (PubMed=25877200)
ST   FGA: 23,26 (DepMap)
ST   Penta D: 9
ST   Penta E: 13,15
ST   TH01: 7
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 23
//
RX   PubMed=3547771; DOI=10.1620/tjem.150.231;
RA   Kobari M., Hisano H., Matsuno S., Sato T., Kan M., Tachibana T.;
RT   "Establishment of six human pancreatic cancer cell lines and their
RT   sensitivities to anti-tumor drugs.";
RL   Tohoku J. Exp. Med. 150:231-248(1986).
//
RX   PubMed=11115575; DOI=10.3892/or.8.1.89;
RA   Sun C.-L., Yamato T., Furukawa T., Ohnishi Y., Kijima H., Horii A.;
RT   "Characterization of the mutations of the K-ras, p53, p16, and SMAD4
RT   genes in 15 human pancreatic cancer cell lines.";
RL   Oncol. Rep. 8:89-92(2001).
//
RX   PubMed=16912165; DOI=10.1158/0008-5472.CAN-06-0721;
RA   Calhoun E.S., Hucl T., Gallmeier E., West K.M., Arking D.E.,
RA   Maitra A., Iacobuzio-Donahue C.A., Chakravarti A., Hruban R.H.,
RA   Kern S.E.;
RT   "Identifying allelic loss and homozygous deletions in pancreatic
RT   cancer without matched normals using high-density single-nucleotide
RT   polymorphism arrays.";
RL   Cancer Res. 66:7920-7928(2006).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26216984; DOI=10.1073/pnas.1501605112;
RA   Daemen A., Peterson D., Sahu N., McCord R., Du X.-N., Liu B.,
RA   Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R.,
RA   Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R.L.,
RA   Manning G., Settleman J., Hatzivassiliou G., Evangelista M.;
RT   "Metabolite profiling stratifies pancreatic ductal adenocarcinomas
RT   into subtypes with distinct sensitivities to metabolic inhibitors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//